Shares of Galectin Therapeutics Inc. (GALT) trade at a significant discount to their 52-week high of $7.13, recorded last December, and hover around $2 as the company prepares to present new data from its MASH cirrhosis trial.
Metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis, formerly known as nonalcoholic steatohepatitis (NASH) cirrhosis, is the end stage of MASH, a type of liver disease. In MASH cirrhosis, scar tissue and regenerative nodules resulting from the inflammation and fibrosis of NASH replace healthy liver tissue, preventing the liver from functioning normally.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com